Ginkgo Bioworks Holdings, Inc.
DNA
$7.54
-$0.27-3.46%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 26.16% | 60.65% | -30.24% | -52.98% | -64.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.16% | 60.65% | -30.24% | -52.98% | -64.64% |
| Cost of Revenue | 45.55% | 73.38% | -24.18% | -58.87% | -78.12% |
| Gross Profit | 21.61% | 58.83% | -31.99% | -50.72% | -58.65% |
| SG&A Expenses | -20.12% | -36.25% | -31.46% | -36.92% | -32.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | 123.76% | -- | -- |
| Total Operating Expenses | -26.89% | -42.47% | -15.57% | -27.16% | -37.96% |
| Operating Income | 38.86% | 72.52% | 8.56% | 17.49% | 25.23% |
| Income Before Tax | 49.10% | 81.26% | -25.25% | 19.04% | -12.80% |
| Income Tax Expenses | -64.14% | -1,604.55% | 183.58% | -62.20% | 98.66% |
| Earnings from Continuing Operations | 49.20% | 81.38% | -25.31% | 19.06% | -22.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 49.20% | 81.38% | -25.31% | 19.06% | -20.65% |
| EBIT | 38.86% | 72.52% | 8.56% | 17.49% | 25.23% |
| EBITDA | 44.39% | 79.25% | 9.35% | 16.09% | 25.08% |
| EPS Basic | 53.33% | 82.62% | -17.91% | 22.67% | -13.16% |
| Normalized Basic EPS | 41.68% | 78.14% | 16.67% | 21.40% | 17.30% |
| EPS Diluted | 53.37% | 82.61% | -17.53% | 22.65% | -11.36% |
| Normalized Diluted EPS | 41.64% | 78.14% | 16.68% | 21.36% | 17.28% |
| Average Basic Shares Outstanding | 8.84% | 7.12% | 6.28% | 4.67% | 6.62% |
| Average Diluted Shares Outstanding | 8.78% | 7.13% | 6.29% | 4.63% | 6.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
